Thermo Fisher Scientific CD253 (TRAIL) Monoclonal Antibody (RIK-2), PE, eBioscience

Applications

Tested Dilution

Publications

Flow Cytometry (Flow)

5 µL (0.06 µg)/test

View 4 publications 4 publications

Product Specifications

Species Reactivity

Human

Published species

Human

Host/Isotype

Mouse / IgG1, kappa

Recommended Isotype Control

Mouse IgG1 kappa Isotype Control (P3.6.2.8.1), PE, eBioscience™

Class

Monoclonal

Type

Antibody

Clone

RIK-2

Conjugate

PE PE PE

View additional formats

• Functional Grade
• Request custom conjugation

Excitation/Emission Max

565/576 nm View spectra

Form

Liquid

Concentration

5 µL/Test

Purification

Affinity chromatography

Storage buffer

PBS, pH 7.2, with 0.2% BSA

Contains

0.09% sodium azide

Storage conditions

4° C, store in dark, DO NOT FREEZE!

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_10557246

Product Specific Information

Description: The RIK-2 monoclonal antibody reacts with human TNF-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily. TRAIL is not expressed by resting human cells but has been shown to be induced under certain activation conditions. Iin addition it is expressed on several human tumor lines. Interaction of TRAIL with its ligand, Apo-2, induces apoptosis. RIK-2 blocks TRAIL-induced apoptosis.

Applications Reported: The RIK-2 antibody has been reported for use in flow cytometric analysis.

Applications Tested: The RIK-2 antibody has been pre-titrated and tested by flow cytometric analysis of human TRAIL transfected cells. This can be used at 5 µL (0.06 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.

Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser.

Filtration: 0.2 µm post-manufacturing filtered.

Target Information

TRAIL is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. TRAIL preferentially induces apoptosis in transformed and tumor cells, but does not appear to kill normal cells although it is expressed at a significant level in most normal tissues. TRAIL binds to several members of TNF receptor superfamily including TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4, and possibly also to TNFRSF11B/OPG. The activity of this protein may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4, and TNFRSF11B/OPG that cannot induce apoptosis. The binding of TRAIL protein to its receptors has been shown to trigger the activation of MAPK8/JNK, caspase 8, and caspase 3. Receptors for TRAIL include two death domain containing receptors, death receptor 4 (DR4) and DR5, as well as two decoy receptors, DcR1 and DcR2, lacking the intracellular signaling death domain. TRAIL is a type II membrane protein and expressed in a variety of human tissues. Like TNF and Fas ligand, TRAIL induces apoptosis and NF-kB activation in many tissues and cells.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.